GRI Bio Reported FY23 Net Loss of $(13.0)M, Cash Balance of $1.8M
Portfolio Pulse from Benzinga Newsdesk
GRI Bio reported a net loss of $13.0 million for the fiscal year 2023, with a remaining cash balance of $1.8 million.
April 01, 2024 | 11:38 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
GRI Bio reported a significant net loss of $13.0 million for FY23, alongside a low cash balance of $1.8 million.
The reported net loss and low cash balance indicate financial struggles for GRI Bio, likely leading to negative investor sentiment and a potential decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100